These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 8073305)

  • 1. MINE-ESHAP salvage therapy for recurrent and refractory lymphomas.
    Cabanillas F; Rodriguez MA
    Semin Hematol; 1994 Apr; 31(2 Suppl 3):30. PubMed ID: 8073305
    [No Abstract]   [Full Text] [Related]  

  • 2. A phase II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplatin as salvage therapy for relapsing and/or refractory lymphomas.
    Romaguera JE; Rodriguez MA; Hagemeister FB; McLaughlin P; Swan F; Moore DF; Sarris AH; Younes A; Hill D; Cabanillas F
    Invest New Drugs; 1994; 12(3):217-22. PubMed ID: 7896540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP.
    Rodriguez MA; Cabanillas FC; Velasquez W; Hagemeister FB; McLaughlin P; Swan F; Romaguera JE
    J Clin Oncol; 1995 Jul; 13(7):1734-41. PubMed ID: 7602363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experience with salvage regimens at M.D. Anderson Hospital.
    Cabanillas F
    Ann Oncol; 1991 Jan; 2 Suppl 1():31-2. PubMed ID: 1904269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-Hodgkin's lymphomas: a review of the M.D. Anderson experience.
    Cabanillas F
    Semin Oncol; 1992 Feb; 19(1 Suppl 1):11-3. PubMed ID: 1384134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ifosfamide- and etoposide-based chemotherapy as salvage and mobilizing regimens for poor prognosis lymphoma.
    Mayer J; Vásová I; Korístek Z; Navrátil M; Klabusay M; Doubek M; Vorlícek J; Cernilová I; Vodvárka P; Petráková K
    Eur J Haematol Suppl; 2001 Jul; 64():21-7. PubMed ID: 11486396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term follow-up of platinum-based lymphoma salvage regimens. The M.D. Anderson Cancer Center experience.
    Rodriguez-Monge EJ; Cabanillas F
    Hematol Oncol Clin North Am; 1997 Oct; 11(5):937-47. PubMed ID: 9336723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ninety-six-hour paclitaxel infusion with mitoxantrone and ifosfamide/mesna and consolidation with ESHAP for refractory and relapsed non-Hodgkin's lymphoma.
    Romaguera JE; Hagemeister FB; McLaughlin P; Rodriguez MA; Bachier C; Preti H; Sarris AH; Weber D; Younes A; Cabanillas F
    Leuk Lymphoma; 1998 Dec; 32(1-2):97-106. PubMed ID: 10037005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiation therapy after a partial response to CHOP chemotherapy for aggressive lymphomas.
    Wilder RB; Rodriguez MA; Tucker SL; Ha CS; Hess MA; Cabanillas FF; Cox JD
    Int J Radiat Oncol Biol Phys; 2001 Jul; 50(3):743-9. PubMed ID: 11395243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose infusional ifosfamide, etoposide plus methylprednisolone followed by dexamethasone, high-dose ara-C and cisplatinum and autologous stem cell transplantation for refractory or relapsed aggressive non-Hodgkin's lymphoma.
    Salar A; Martino R; Perea G; Ribera JM; López-Guillermo A; Guardia R; Escoda L; Altés A; Sierra J; Montserrat E
    Haematologica; 2002 Oct; 87(10):1028-35. PubMed ID: 12368156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Combination chemotherapy with VP-16 in the treatment of lung cancer and malignant lymphoma].
    Hosomi Y; Shibuya M
    Gan To Kagaku Ryoho; 2001 Oct; 28(10):1352-6. PubMed ID: 11681241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas.
    Rodriguez MA; Cabanillas FC; Hagemeister FB; McLaughlin P; Romaguera JE; Swan F; Velasquez W
    Ann Oncol; 1995 Jul; 6(6):609-11. PubMed ID: 8573542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Chemotherapy of resistant and recurrent lymphoma based on a combination of ifosfamide and etoposide. Antitumor effects, toxicity and stimulation of peripheral stem cells].
    Mayer J; Korístek Z; Vásová I; Müllerová I; Král Z; Navrátil M; Klabusay M; Vorlícek J; Vodvárka P; Hejlová N; Penka M; Krahulcová E; Tomíska M; Adam Z; Hájek R
    Cas Lek Cesk; 1998 Oct; 137(19):590-7. PubMed ID: 9818471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
    Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
    Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparison of salvage chemotherapy regimen ACES with ESHAP for refractory or relapsed malignant lymphoma].
    Imataki O; Tamai Y; Kawakami K
    Gan To Kagaku Ryoho; 2007 Oct; 34(10):1629-32. PubMed ID: 17940378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study.
    Martín A; Conde E; Arnan M; Canales MA; Deben G; Sancho JM; Andreu R; Salar A; García-Sanchez P; Vázquez L; Nistal S; Requena MJ; Donato EM; González JA; León A; Ruiz C; Grande C; González-Barca E; Caballero MD;
    Haematologica; 2008 Dec; 93(12):1829-36. PubMed ID: 18945747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
    Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
    Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ESHAP chemotherapy for relapsed/refractory non-Hodgkin's lymphoma.
    Sweetenham JW; Johnson PW
    J Clin Oncol; 1994 Dec; 12(12):2766. PubMed ID: 7989954
    [No Abstract]   [Full Text] [Related]  

  • 20. Salvage chemotherapy with alternating MINE-ESHAP regimen in relapsed or refractory Hodgkin's lymphoma followed by autologous stem-cell transplantation.
    Fernández de Larrea C; Martínez C; Gaya A; López-Guillermo A; Rovira M; Fernández-Avilés F; Lozano M; Bosch F; Esteve J; Nomdedeu B; Montserrat E; Carreras E
    Ann Oncol; 2010 Jun; 21(6):1211-1216. PubMed ID: 19889622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.